Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice

Maura Corsetti*, Sylvie Forestier, Marcel Jiménez

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticle de revisióRecercaAvaluat per experts

3 Cites (Scopus)

Resum

Background: Hyoscine butylbromide (HBB) has been available for use as an antispasmodic since 1951 and is indicated for the treatment of abdominal pain associated with cramps. A previous review in 2007 summarized the evidence on the mode of action of HBB in vitro and in vivo in both animal and human studies. However, since then, novel publications have appeared within the literature and also our knowledge of what represents normal motility in humans has evolved. Purpose: This review is the result of the collaboration between a basic scientist and clinicians with the aim of providing an updated overview of the mechanisms of action of HBB and its clinical efficacy to guide not only use in clinical practice, but also future research.
Idioma originalEnglish
Número d’articlee14451
Nombre de pàgines13
RevistaNeurogastroenterology and Motility
Volum35
Número4
DOIs
Estat de la publicacióPublicada - d’abr. 2023

Fingerprint

Navegar pels temes de recerca de 'Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice'. Junts formen un fingerprint únic.

Com citar-ho